A macrolide compound represented by the formula (I) effective against erythromycin resistant bacteria (for example, resistant pneumococci, streptococci and mycoplasmas).
The invention provides new heterocyclic compounds having the general Formula (I), or a pharmaceutically acceptable salt thereof,
wherein R
1
, R
2
, X, Y
1
and Y
2
are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.